<u>Supplemental Figure 2-</u> Cell numbers of multiple immune cell substes, and mainly dendritic cells, are deacresed over time in melnaonma tumors. **(A)** Mean percentages of immune cell subsets that infiltrate B16F10 tumors on early (day 6) and late (day 14) stage. **(B)** Mean percentages of immune cell subsets that infiltrate *ret* tumors on early (day 6) and late (day 14) stage. **(C)** Mean percentages of immune cell subsets in the DLN of B16F10 tumor-bearing mice from early (day 6) and late (day 14) stage. **(D)** Mean percentages of immune cell subsets in the DLN of *ret* tumor-bearing mice from early (day 6) and late (day 14) stage. **(E)** Gating strategy of tumor infiltrating myeloid cells flow cytometry analysis. **(F)** Mean numbers (left graph) and percentages (right graph) of tumor-infiltrating pan DC. **(G)** Histological sections of wasabi-labeled B16F10 tumors from early-stage (day 8). **(H)** Mean percentages of BrdU incorporation in CD8$^+$ in the DLN of B16F10 tumor-bearing mice.